Christian Pifl

Prof. Dr. Christian Pifl


Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2017 in Nature Biotechnology
Verified
Journal Article
Closed access
PCPia Rivetti di Val Cervo
Pia Rivetti di Val Cervo
RRRoman A. Romanov
Roman A. Romanov
GSGiada Spigolon
Giada Spigolon
DMDébora Masini
Débora Masini
EMElisa Martín-Montañez
Elisa Martín-Montañez
EAErnest Arenas
Ernest Arenas

24 March 2005 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
JXJin Xu
Jin Xu
NZNan Zhong
Nan Zhong
HWHaoyong Wang
Haoyong Wang
JEJoshua E. Elias
Joshua E. Elias
CKChristina Y. Kim
Christina Y. Kim
BYBruce A. Yankner
Bruce A. Yankner
Mutations in the DJ-1 gene cause early-onset autosomal recessive Parkinson's disease (PD), although the role of DJ-1 in the degeneration of dopaminergic neurons is unresolved. Here we show that the major interacting-proteins with DJ-1 in dopaminergic neuronal cells are the nuclear proteins p54nrb and pyrimidine tract-binding protein-associated splicing factor (PSF), two multifunctional regulators of transcription and RNA metabolism. PD-associated DJ-1 mutants exhibit decreased nuclear distribution and increased mitochondrial localization, resulting in diminished co-localization with co-activator p54nrb and repressor PSF. Unlike pathogenic DJ-1 mutants, wild-type DJ-1 acts to inhibit the transcriptional silencing activity of the PSF. In addition, the transcriptional silencer PSF induces neuronal apoptosis, which can be reversed by wild-type DJ-1 but to a lesser extent by PD-associated DJ-1 mutants. DJ-1-specific small interfering RNA sensitizes cells to PSF-induced apoptosis. Both DJ-1 and p54nrb block oxidative stress and mutant α-synuclein-induced cell death. Thus, DJ-1 is a neuroprotective transcriptional co-activator that may act in concert with p54nrb and PSF to regulate the expression of a neuroprotective genetic program. Mutations that impair the transcriptional co-activator function of DJ-1 render dopaminergic neurons vulnerable to apoptosis and may contribute to the pathogenesis of PD.

1 November 2009 in Nature
Verified
Journal Article
Closed access
PDF file
RHReiko Hanada
Reiko Hanada
ALAndreas Leibbrandt
Andreas Leibbrandt
THToshikatsu Hanada
Toshikatsu Hanada
SKShiho Kitaoka
Shiho Kitaoka
TFTomoyuki Furuyashiki
Tomoyuki Furuyashiki
JPJosef M Penninger
Josef M Penninger

1 September 1996 in Neurology
Verified
Journal Article
Closed access
PDF file
JWJ. M. Wilson
J. M. Wilson
ALA. I. Levey
A. I. Levey
ARA. Rajput
A. Rajput
LAL. Ang
L. Ang
MGM. Guttman
M. Guttman
SKS. J. Kish
S. J. Kish
To determine the extent that different dopamine (DA) neuronal markers provide similar estimates of striatal (caudate and putamen) DA nerve terminal loss in idiopathic Parkinson9s disease (PD), we compared, in postmortem striatum of 12 patients with PD and 10 matched controls, levels of five different DA neuronal markers.These markers included DA itself, three different estimates of the density of the DA transporter (DAT) ([sup 3 H]GBR 12,935 and [sup 3 H]WIN 35,428 binding; DAT protein immunoreactivity), and one estimate of the vesicular monoamine transporter (VMAT2; [sup 3 H]DTBZ binding). Striatal levels of all examined DA markers in PD were significantly intercorrelated. However, the magnitude of loss relative to controls was unequal (DAT protein = DA > [sup 3 H]WIN 35,428 > [sup 3 H]DTBZ > [sup 3 H]GBR 12,935), with the differences more marked in the severely affected putamen. The less severe reduction of binding of the DAT/VMAT2 radioligands relative to DA and DAT protein could be explained by differential regulation/degeneration of different DA nerve terminal components or lack of specificity of the radioligands for the DA neuron. These postmortem data may help in interpretation of in vivo neuroimaging studies in PD in which only one radioligand is routinely employed. NEUROLOGY 1996;47: 718-726

1 September 1998 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
HSHarald H. Sitte
Harald H. Sitte
SHS. Huck
S. Huck
HRH. Reither
H. Reither
Stefan BoehmStefan Boehm
Stefan Boehm
ESE. A. Singer
E. A. Singer
CPChristian Pifl
Christian Pifl
Amphetamine and related substances induce dopamine release. According to a traditional explanation, this dopamine release occurs in exchange for amphetamine by means of the dopamine transporter (DAT). We tested this hypothesis in human embryonic kidney 293 cells stably transfected with the human DAT by measuring the uptake of dopamine, tyramine, and d‐ and l‐amphetamine as well as substrate‐induced release of preloaded N‐methyl‐4‐[3H]phenylpyridinium ([3H]MPP+). The uptake of substrates was sodium‐dependent and was inhibited by ouabain and cocaine, which also prevented substrate‐induced release of MPP+. Patch‐clamp recordings revealed that all four substrates elicited voltage‐dependent inward currents (on top of constitutive leak currents) that were prevented by cocaine. Whereas individual substrates had similar affinities in release, uptake, and patch‐clamp experiments, maximal effects displayed remarkable differences. Hence, maximal effects in release and current induction were ∼25% higher for d‐amphetamine as compared with the other substrates. By contrast, dopamine was the most efficacious substrate in uptake experiments, with its maximal initial uptake rate exceeding those of amphetamine and tyramine by factors of 20 and 4, respectively. Our experiments indicate a poor correlation between substrate‐induced release and the transport of substrates, whereas the ability of substrates to induce currents correlates well with their releasing action.

15 April 2008 in Neurology
Verified
Journal Article
Closed access
PDF file
ARA. H. Rajput
A. H. Rajput
HSHarald H. Sitte
Harald H. Sitte
ARA. Rajput
A. Rajput
MFM. E. Fenton
M. E. Fenton
CPChristian Pifl
Christian Pifl
OHO. Hornykiewicz
O. Hornykiewicz
Background: Patients with Parkinson disease (PD) may be akinetic/rigid, be tremor dominant, or have comparable severity of these motor symptoms (classic). The pathophysiologic basis of different PD phenotypes is unknown. This study assessed pallidal and striatal dopamine level patterns in different motor subgroups of PD and normal control brains.